Top 5 Stocks to Buy for July 2026: AI, Power, Pharma

That capex supercycle has also concentrated market leadership. Analysts at several firms have pointed to a narrower set of well-documented AI bottlenecks, namely power generation, advanced memory, and thermal management, as the areas most likely to keep benefiting even if broader AI enthusiasm cools. At the same time, defensive sectors such as healthcare and regulated utilities have offered a counterweight for investors wary of concentration risk in a market where the largest constituents account for an outsized share of index returns.

Gold Compass Daily’s equity desk screened this environment for five names that combine strong fundamentals, credible forward guidance, and clear positioning within structural growth themes for July. The list below spans semiconductors, data center infrastructure, utilities, and pharmaceuticals, offering diversification alongside AI-cycle exposure. As with any equity selection, individual positions should be sized according to an investor’s own risk tolerance, time horizon, and existing portfolio composition.

1. Micron Technology (NASDAQ: MU)

Micron has been one of the standout performers of the current market cycle. The stock traded near $1,145 to $1,155 as June closed, having gained roughly 829% over the trailing twelve months, and it crossed the $1 trillion market capitalization threshold in late May amid surging demand for its high-bandwidth memory, or HBM, chips. The rally has been underpinned by fundamentals rather than sentiment alone: fiscal third-quarter 2026 results showed record revenue of $41.46 billion and earnings per share of $25.11, comfortably ahead of the $35.3 billion consensus estimate.

The core investment thesis rests on structural supply tightness in memory. The global HBM market is effectively controlled by three suppliers, SK Hynix, Samsung, and Micron, all of which have committed their available capacity through 2026. Micron has used that scarcity to raise prices and shift customers toward long-term supply agreements, a combination that management and analysts describe as improving both margin durability and revenue visibility. The company has also disclosed that its HBM output is sold out through 2026, a detail that has repeatedly been cited by sell-side desks as a key catalyst supporting further upside.

According to data compiled by CNN and StockAnalysis.com, the average analyst rating on Micron stands at Strong Buy, with a twelve-month consensus price target near $1,454, implying approximately 27% upside from recent levels. Micron has also broadened its footprint beyond memory supply agreements, announcing a strategic partnership with Anthropic in June to help scale next-generation AI infrastructure, alongside continued domestic manufacturing expansion, including a New York semiconductor project built with Bechtel as construction partner and additional capacity investment in Virginia.

Risks are worth flagging directly. Micron faces a newly filed price-fixing lawsuit alongside Samsung and SK Hynix related to memory pricing practices, and several commentators have noted the stock’s valuation now sits well above traditional discounted cash flow estimates, suggesting a meaningful premium is being paid for the current supply-demand imbalance. Competitive dynamics also bear watching: SK Hynix is expected to begin trading on the Nasdaq as early as July 10, and some analysts have suggested that listing event could introduce near-term volatility into the memory trade. Investors should treat Micron as a higher-beta, cyclical exposure to the AI infrastructure buildout rather than a defensive holding.

2. Vertiv Holdings (NYSE: VRT)

Vertiv sits at the center of what analysts have called the “picks-and-shovels” layer of the AI boom, supplying power management and thermal, or cooling, infrastructure to data centers. The stock has risen more than 100% year-to-date and traded in the $300 to $330 range in late June, following a strong Analyst Day that prompted a wave of price target increases from firms including Roth Capital, Oppenheimer, Barclays, and Bernstein.

First-quarter 2026 results illustrated the scale of demand Vertiv is capturing. Net sales reached $2.65 billion, up 30% year over year, with the Americas segment growing 44% organically and adjusted diluted earnings per share of $1.17 beating prior guidance by $0.19, a roughly 83% year-over-year increase. Adjusted free cash flow of approximately $653 million was up around 147% from the prior year. Management has guided EPS growth toward the 51% range for the year and highlighted a backlog cited by multiple analysts at roughly $15 billion, giving visibility well beyond the current quarter.

Vertiv has continued to expand its addressable market through acquisitions, including ThermoKey and Strategic Thermal Labs, both aimed at broadening liquid cooling and thermal architecture capabilities as AI compute density increases. The company has also been named as an infrastructure partner in Nvidia’s Vera Rubin data center reference design, underscoring its role in next-generation AI factory build-outs. Independent research has pointed to the global data center liquid cooling market growing from roughly $5.7 billion in 2026 to $29.2 billion by 2033, a structural tailwind that supports Vertiv’s multi-year growth narrative.

Analyst sentiment is firmly bullish. Coverage compiled by TIKR shows 18 buy ratings and 4 outperform ratings against only a small number of holds, with a mean price target near $377 and a Street-high target of $500, implying meaningful upside from current levels even after the stock’s strong run. The primary swing factor cited by analysts is whether Vertiv’s EMEA segment, which has lagged the Americas recovery, begins showing growth in the second half of the year as management has guided. Given the stock’s rich valuation, with a trailing price-to-earnings ratio above 75, Vertiv should be viewed as a growth-oriented position whose near-term price action will likely remain sensitive to data center capex headlines.

3. NextEra Energy (NYSE: NEE)

NextEra Energy offers a different entry point into the AI infrastructure theme: power generation rather than compute or cooling hardware. As the largest regulated utility and renewable energy operator in the United States, NextEra is positioned to benefit from surging electricity demand tied to data center construction, a dynamic increasingly described by utility analysts as one of the defining stories of the current power cycle.

The stock traded near $88 to $92 through late June, and first-quarter 2026 results beat expectations, with adjusted earnings per share of $1.09 topping forecasts by more than 12%. Management has maintained full-year 2026 adjusted EPS guidance of $3.92 to $4.02, targeting the high end of that range, alongside a longer-term commitment to greater than 8% compound annual earnings growth through 2032. The company’s Florida Power & Light utility segment is projecting a 9% compound annual growth rate in regulated capital, while its renewables arm, NextEra Energy Resources, expects adjusted EBITDA and EPS to grow at roughly 16% and 13% respectively through 2027.

Supply chain security is a notable strength in the current guidance. NextEra has disclosed that it has secured solar panel and battery supply through 2029, wind components through 2027, and sufficient transformer capacity through the end of the decade, insulating near-term project execution from tariff and trade disruptions that have weighed on some renewable energy peers. The company has also launched a Rewire initiative in partnership with Google Cloud, applying AI tools to grid optimization, equipment monitoring, and dispatch efficiency, an example of the utility sector’s own adoption of the technology it is increasingly powering.

A pending, and closely watched, corporate development is NextEra’s proposed roughly $67 billion all-stock acquisition of Dominion Energy, which would meaningfully expand its regulated asset base but is currently facing scrutiny over potential anticompetitive concerns. Investors should treat the deal’s outcome as a source of event risk for the stock over the coming quarters. NextEra carries a dividend yield in the 2.5% to 2.7% range, with a dividend that has grown at an average annual rate of roughly 12% over the past decade, offering income alongside growth exposure. Wall Street’s consensus rating remains Buy, with price targets clustered near $100 to $111, though the utility’s above-average valuation relative to sector peers reflects its premium growth profile rather than a traditional defensive utility discount.

4. Taiwan Semiconductor Manufacturing Company (NYSE: TSM)

Taiwan Semiconductor remains the foundational supplier to the global AI chip ecosystem, manufacturing advanced logic chips for Nvidia, Apple, AMD, and effectively every major fabless semiconductor company. With an estimated 70% share of the global dedicated foundry market and a market capitalization near $2.26 trillion, TSMC’s scale advantage in leading-edge process technology remains largely unmatched.

At its annual shareholder meeting in early June, CEO C.C. Wei raised the company’s 2026 revenue growth forecast to more than 30%, up from an earlier estimate of 25% given in January, citing sustained AI infrastructure investment. That guidance was corroborated by first-quarter foundry market data showing global sector revenue up 23% year over year to $86 billion, with TSMC alone posting 41% revenue growth and capturing the largest share of that expansion. Advanced technologies, defined as chips built on 7-nanometer processes or smaller, now account for roughly three-quarters of TSMC’s total wafer revenue, reflecting the shift of its business mix toward the highest-margin, highest-demand segments of the market.

The stock has traded in a broad range through June, moving toward its 52-week high near $477 amid a string of analyst upgrades ahead of second-quarter results scheduled for July 16. Barclays raised its price target to $625 from $470 while maintaining an Overweight rating, citing capital expenditure estimates of $56 billion for 2026 and $74 billion for 2027, and flagging TSMC as a top pick heading into earnings alongside SK Hynix, ASML, and ASM International. Bank of America separately lifted its target to $590 from $490, citing growing demand tied to agentic AI applications. UBS has projected TSMC could raise advanced-process pricing by 5% to 10% as early as the first quarter of 2027, a potential structural tailwind for margins that has resonated with investors positioning ahead of earnings.

Investors should be mindful of geopolitical concentration risk, given TSMC’s manufacturing base is centered in Taiwan, along with capacity constraint headlines that have periodically pushed customers such as AMD, Google, and BYD to explore supplementary foundry relationships with Samsung. Valuation has also expanded meaningfully alongside the stock’s rally, with some models flagging the shares as trading at a premium to intrinsic value estimates. That said, the combination of dominant market share, raised revenue guidance, and expanding advanced-node demand gives TSMC a structural position in the AI supply chain that few competitors can replicate.

5. AbbVie (NYSE: ABBV)

AbbVie offers a defensive counterweight to the AI infrastructure theme, anchored in a pharmaceutical business that has successfully navigated the loss of patent exclusivity on its former blockbuster drug, Humira. The company’s immunology franchise, led by Skyrizi and Rinvoq, has emerged as the primary growth engine, and results through the first half of 2026 have consistently outpaced both management’s own guidance and Street expectations.

First-quarter 2026 revenue reached $15 billion, up 12% year over year, with adjusted diluted earnings per share of $2.65, an increase of 7.7% from the prior-year period. Skyrizi sales rose 29.2% year over year to $4.48 billion, while Rinvoq generated $2.12 billion, up 20.2%, driven by continued market share gains across dermatology, rheumatology, and gastroenterology indications. Management raised full-year 2026 revenue guidance to approximately $67.3 billion and lifted combined peak sales targets for Skyrizi and Rinvoq to $21.6 billion and $10.2 billion respectively, targets that executives have said the Street continues to undermodel. Full-year adjusted diluted earnings per share guidance was raised to a range of $14.08 to $14.28.

The scale of the immunology turnaround is notable in historical context. Combined Skyrizi and Rinvoq revenue already exceeded AbbVie’s own prior 2027 target of $27 billion two years ahead of schedule, and combined sales have now surpassed peak Humira revenue by more than $4.5 billion. Beyond immunology, AbbVie’s neuroscience segment grew 24% operationally in the most recent quarter, with newer therapies including Vyalev, a continuous Parkinson’s disease treatment, tracking toward blockbuster status.

Analyst sentiment remains constructive, with roughly 21 to 22 of 29 covering analysts rating the stock a buy or outperform, according to data compiled by TIKR, and mean price targets in the $248 to $249 range representing meaningful upside from recent trading levels near $208 to $220. AbbVie trades at approximately 14 to 15 times 2026 estimated earnings, a discount to its own five-year historical valuation range even as earnings growth is accelerating rather than decelerating. The stock also offers a dividend yield that has made it a recurring name on dividend-focused screens for July, supported by a payout that management has continued to grow annually. Risks include Medicare pricing negotiations affecting Botox beginning in 2028 and Inflation Reduction Act-related pricing pressure on oncology products such as Imbruvica, both of which bear watching as multi-year overhangs rather than near-term catalysts.

How These Five Names Fit Together

The selections above are intentionally diversified across the AI infrastructure value chain and beyond it. Micron and Taiwan Semiconductor offer direct exposure to chip supply constraints, in memory and advanced logic manufacturing respectively, that have driven some of the sharpest re-ratings in the market over the past year. Vertiv provides exposure to the physical infrastructure, power and cooling, required to deploy that compute at scale, while NextEra Energy addresses the electricity generation capacity that ultimately constrains how quickly data centers can be built and energized. AbbVie stands apart from the AI theme entirely, offering earnings durability and dividend income from a business model insulated from semiconductor cycles and data center capex swings.

Investors should weigh position sizing carefully given the divergent risk profiles at play. Micron, Vertiv, and TSMC carry elevated valuations and higher sensitivity to any deceleration in AI infrastructure spending, a scenario several strategists have flagged as a tail risk should hyperscaler capital expenditure guidance disappoint later in the year. NextEra carries deal-related uncertainty tied to its pending Dominion Energy acquisition. AbbVie’s risks are longer-dated and more predictable, centered on pricing regulation rather than demand uncertainty. Taken together, the five names offer a framework for building AI-cycle exposure while retaining a ballast position that does not depend on the continuation of the current capital spending supercycle.

Disclaimer

This article is provided for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Stock prices, analyst ratings, and price targets referenced above reflect data available as of late June 2026 and are subject to change without notice. Past performance is not indicative of future results. Readers should conduct their own due diligence and consult a licensed financial advisor before making investment decisions.

Gold Compass Daily | Published July 1, 2026, 09:00 UTC+3